Business Wire

VALBIOTIS

19.5.2021 17:42:10 CEST | Business Wire | Press release

Share
Valbiotis Obtains Patent for Its Active Substance TOTUM•63 in China, a Large Potential Market for the Prevention of Type 2 Diabetes and Metabolic Diseases

Regulatory News:

Valbiotis (FR0013254851 - ALVAL, eligible for the PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces that it has obtained a patent in China for TOTUM•63, issued by the China National Intellectual Property Administration (CNIPA). This patent protects the composition and use of TOTUM•63 for the prevention of type 2 diabetes and metabolic diseases until 2035. China, whose economic development has been accompanied by an explosion of metabolic disorders since the 2000s, is now believed to have the largest prediabetic population in the world, with an estimated 390 million people (35% of the adult population)1 .

Sébastien PELTIER, CEO of Valbiotis, comments: "We are honored to obtain this Chinese patent. It is the recognition of our ability to develop plant-based active substances by another major global market, after Europe and the United States. In this new and rapidly developing territory, metabolic diseases and type 2 diabetes are critical public health issues. With this patent, we can now envision making our active substance TOTUM•63 available to a very large population, whose need for the prevention of metabolic diseases is huge. This is an exciting prospect and a challenge that we will undertake with great determination, alongside our partner Nestlé Health Science."

The rise of a significant market for the prevention of metabolic diseases in China

Since the 2000s and the acceleration of its economic development, China has been facing a dramatic increase in excess weight, obesity and the associated metabolic diseases such as type 2 diabetes. The rapid change in eating habits and living conditions in the world's largest population has led to an alarming situation for the Chinese authorities: at the end of 2020, 34% of adults in China were overweight and 16% obese, i.e. one adult in two at metabolic risk, an increase of 20% in 20 years2 .
As a result of this weight gain in all age groups, blood glucose disorders are becoming more prevalent in the country: the most recent estimates indicate a 35% prevalence of prediabetes among adults, while type 2 diabetes is almost at 11%1 . These rates are now equivalent to those recorded in the United States, but in a population four times larger. 390 million adults in China are supposed to be prediabetic1 , compared to 86 million in the United States3 .

To meet the new health needs of the population, the Chinese healthcare market has grown rapidly, driven by structural reforms and the development of the middle class4 . In 2018, China ranked 2nd in the global pharmaceutical market (8.2% of global sales), behind the United States5 .

TOTUM•63 now benefits from global patent protection, including in China and 4 other new countries

The patent obtained in China gives exclusive rights to use TOTUM•63 within Chinese territory until 2035. Like the patents already obtained, this patent grants extensive rights that protect, in particular: the active substance TOTUM•63's plant extract and biomolecule composition, the possible combination with other products or substances and, above all, the specific use of this innovation in the field of metabolic diseases.

In addition to China, similar patents for TOTUM•63 have recently been obtained in Japan, Mexico, Indonesia and New Zealand, bringing the total number of countries in which TOTUM•63 is now protected to 48.

TOTUM•63 patent is the subject of a global patent filing strategy in more than 60 countries, including Europe and North America. It is co-owned along with the CNRS (Centre National de la Recherche Scientifique), Clermont Auvergne University and La Rochelle University, each long-standing academic partners of Valbiotis since the Company's creation in 2014.

About TOTUM•63
TOTUM•63 is a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of Type 2 Diabetes.
TOTUM•63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study. The results of the international randomized, placebo-controlled Phase II study showed that TOTUM•63 reduced fasting and 2-hour blood sugar levels, two risk factors for Type 2 Diabetes, in prediabetics compared to placebo. In these subjects, who also had abdominal obesity, TOTUM•63 significantly reduced body weight and waist circumference.
TOTUM•63 benefits from intellectual property granted in the main markets worldwide: Europe (covering 39 countries), the United States, Russia, China, Japan, Mexico, Indonesia, Israel, South Africa, New-Zealand and national phases are underway in more than 10 countries including Brazil and Australia. The ability to produce TOTUM•63 industrially, in compliance to North American and European standards, has been validated. TOTUM•63 already has marketing authorizations related to its status in Europe.
In 2020, Valbiotis has signed a global and long-term partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM•63. This unique partnership in the field of Nutrition Health plans that TOTUM•63 will be put on the market by Nestlé Health Science at a global level, possibly before obtaining a health claim, depending on the areas. It will also provide funding for the latest development stages of TOTUM•63.

About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France: Périgny, La Rochelle (17) and Riom (63).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, approved by the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com ).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.

1 Limin Wang et al . JAMA. 2017;317(24):2515-2523.
2 Chinese national nutrition and chronic disease report 2020, National Health Commission, www.sciencesetavenir.fr/sante/plus-d-un-chinois-sur-deux-desormais-en-surpoids_150360 (as viewed on April 27, 2021).
3 AEC Partners data on Valbiotis' key markets, 2019.
4 daxueconseil.fr/marche-des-medicaments-en-vente-libre-en-chine/ (as viewed on April 27, 2021).
5 Bilan Economique, Les Entreprises du Médicament, 2019, p. 40 ; www.leem.org/sites/default/files/2019-09/250719-BilanEco2019_6.pdf (as viewed on April 27, 2021).

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 20:10:00 CET | Press release

Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit

Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 19:00:00 CET | Press release

Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide

TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 18:04:00 CET | Press release

Seasoned biotech CFO with gene therapy, diagnostics, IPO and Wall Street experience joins the executive leadership team TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and

Visa Report: AI-Enabled Fraud and Third-Party Attacks Are Scaling Worldwide17.11.2026 16:40:00 CET | Press release

Third-party incidents surged 62%, while Visa Scam Disruption identified more than $1.4 billion in potential fraud Fraud is becoming more automated, targeted and global as criminals use AI to exploit weak points across the payments ecosystem and target third-party providers that can provide access to multiple downstream payment organizations, according to the Visa (NYSE: V) Fall 2026 Biannual Threats Report released today during International Fraud Awareness Week. Developed by Visa Payment Ecosystem Risk and Control (PERC), the report examines threat activity observed between January and June 2026 and finds that AI is not creating entirely new categories of fraud. Instead, it is helping criminals that execute existing attacks faster, at greater scale, and with greater precision, while increasingly targeting third-party providers that can provide access to multiple downstream organizations at once. Although attack volumes increased in several areas, the report also found evidence that co

Sparxity Appoints former Cray CEO Peter Ungaro and Semiconductor Veteran Daniel Armbrust to its Advisory Board17.11.2026 16:00:00 CET | Press release

Appointments bring decades of leadership experience in supercomputing, semiconductor commercialization, and scaling advanced computing business Sparxity, a leader in sparse-native computing, today announced that Peter Ungaro, former President and CEO of Cray, Inc., and Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst, have joined its Advisory Board as independent members. Armbrust has been elected Chairman of the Advisory Board and Ungaro Deputy Chairman by their fellow board members. The appointments strengthen the company’s leadership as it scales its sparse-native computing technology for next-generation AI and high-performance computing (HPC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117761685/en/ From left to right, Daniel Armbrust, former President and CEO of SEMATECH and co-founder of Silicon Catalyst and Peter Ungaro, former President and CEO of Cray, Inc. Peter Ungaro

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye